Clinical and laboratory profiles of the 6 tested patients
| Patients . | Laboratory criteria .  | Clinical manifestations . | ||
|---|---|---|---|---|
| LA . | aCL . | aβ2GP1 IgG . | ||
| Patient 1 | + | > 60 | + | Thromboembolism | 
| Patient 2 | + | > 60 | + | Arterial thrombosis | 
| Patient 3 | + | 36 | + | Recurrent fetal loss | 
| Patient 4 | − | – | + | Venous thrombosis | 
| Patient 5 | + | 35 | + | Venous thrombosis | 
| Patient 6 | − | > 60 | + | Recurrent fetal loss | 
| Patients . | Laboratory criteria .  | Clinical manifestations . | ||
|---|---|---|---|---|
| LA . | aCL . | aβ2GP1 IgG . | ||
| Patient 1 | + | > 60 | + | Thromboembolism | 
| Patient 2 | + | > 60 | + | Arterial thrombosis | 
| Patient 3 | + | 36 | + | Recurrent fetal loss | 
| Patient 4 | − | – | + | Venous thrombosis | 
| Patient 5 | + | 35 | + | Venous thrombosis | 
| Patient 6 | − | > 60 | + | Recurrent fetal loss | 
LA indicates lupus anticoagulant; aCL IgG anticardiolipin antibodies (normal value < 5 IgG antiphospholipid [GPL] units); aβ2GP1 IgG, anti-β2glycoprotein 1 IgG; +, positive; −, negative.